Download PDF
Aktuelle Neurologie 2011; 38: S7-S10
DOI: 10.1055/s-0030-1265946
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Apomorphintest

The Apomorphine TestK.  Eggert1 , W.  H.  Oertel1
  • 1Neurologische Klinik, Philipps-Universität Marburg
Further Information

Publication History

Publication Date:
22 February 2011 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Apomorphin ist ein Non-Ergot-Dopaminagonist, dessen therapeutische Wirksamkeit auf die Kardinalsymptome der Parkinsonkrankheit seit über 100 Jahren bekannt ist. Die subkutane Injektion von Apomorphin wird seit Ende der 80er-Jahre zu diagnostischen Zwecken durchgeführt. Der sog. Apomorphintest kann die Beurteilung der Effektivität einer dopaminergen Therapie sowie die Diagnoseüberprüfung bei Patienten mit neu aufgetretenem oder atypisch verlaufendem Parkinsonsyndrom unterstützen. Dieser Beitrag stellt die klinische Anwendung des Apomorphintests sowie die Ergebnisse einer Metaanalyse und eines systematischen Reviews zur diagnostischen Wertigkeit des Apomorphintests, auch im Vergleich zum akuten L-Dopa-Test und der chronischen L-Dopa-Anwendung vor.

Abstract

Apomorphine is a powerful, non-ergot dopamine agonist and its therapeutical efficacy on the cardinal motor symptoms of Parkinson's disease has been known for more than 100 years. In the late 1980s the subcutaneous injection of apomorphine was introduced in the assessment of Parkinsonian patients. This acute challenge test used to be advocated as being helpful in improving the clinical diagnostic accuracy of Parkinson's disease and in predicting the dopaminergic responsiveness as part of a pre-treatment assessment. We summarise here the clinical management of the apomorphine test as well as the results of a meta-analysis and a systematic review on the diagnostic value of apomorphine in Parkinsonian patients.

Schlüsselwörter

Apomorphin - Apomorphintest - diagnostische Wertigkeit

Keywords

apomorphine - apomorphine test - diagnostic value

Literatur

  • 1 Gancher S T, Woodward W R, Boucher B et al. Peripheral pharmacokinetics of apomorphine in humans.  Ann Neurol. 1989;  26 232-238
    CrossrefPubMedGoogle Scholar
  • 2 Barker R, Duncan J, Lees A J. Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in Parkinsonian syndromes.  Lancet. 1989;  1 675-678
    PubMedGoogle Scholar
  • 3 Oertel W H, Gasser T, Ippisch R et al. Apomorphine test for dopaminergic responsiveness.  Lancet. 1989;  1 1262-1263
    PubMedGoogle Scholar
  • 4 Hughes A J, Lees A J, Stern G M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.  Lancet. 1990;  336 32-34
    CrossrefPubMedGoogle Scholar
  • 5 D’Costa D F, Abbott R J, Pye I F et al. The apomorphine test in parkinsonian syndromes.  J Neurol Neurosurg Psychiatry. 1991;  54 870-872
    CrossrefPubMedGoogle Scholar
  • 6 Hughes A J, Lees A J, Stern G M. Challenge tests to predict the dopaminergic response in untreated Parkinson’s disease.  Neurology. 1991;  41 1723-1725
    PubMedGoogle Scholar
  • 7 Bonuccelli U, Piccini P, Del Dotto P et al. Apomorphine test in De novo Parkinson’s disease.  Funct Neurol. 1992;  7 295-298
    PubMedGoogle Scholar
  • 8 Gasser T, Schwarz J, Arnold G et al. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson’s disease.  Arch Neurol. 1992;  49 1131-1134
    CrossrefPubMedGoogle Scholar
  • 9 Bonuccelli U, Piccini P, Del Dotto P et al. Apomorphine test for dopaminergic responsiveness: a dose assessment study.  Mov Disord. 1993;  8 158-164
    CrossrefPubMedGoogle Scholar
  • 10 Schelosky L, Hierholzer J, Wissel J et al. Correlation of clinical response in apo-morphine test with D2-receptor status as demonstrated by I123IBZM-SPECT.  Mov Disord. 1993;  8 453-458
    CrossrefPubMedGoogle Scholar
  • 11 Ward C D, Gibb W RG. Research diagnostic criteria for Parkinson’s disease.  Adv Neurol. 1990;  53 245-249
    PubMedGoogle Scholar
  • 12 Hughes A J, Daniel S E, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases.  J Neurol Neurosurg Psychiatry. 1992;  55 181-184
    CrossrefPubMedGoogle Scholar
  • 13 Levitan I, Mangone C A, McKee A et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.  J Neurol Neurosurg Psychiatry. 1996;  61 615-620
    PubMedGoogle Scholar
  • 14 Wenning C, Tison F, Ben-Shlomo Y et al. Multi system atrophy: a review of 203 pathologically proven cases.  Mov Disord. 1997;  12 133-147
    CrossrefPubMedGoogle Scholar
  • 15 Hughes A J. Apomorphine test in the assessment of parkinsonian patients: a meta-analysis.  Adv Neurol. 1999;  80 363-368
    PubMedGoogle Scholar
  • 16 Clarke C E, Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease.  J Neurol Neurosurg Psychiatry. 2000;  69 590-594
    CrossrefPubMedGoogle Scholar
  • 17 Rossi P, Colosimo C, Moro E et al. Acute challenge with apomorphin and levodopa in parkinsonism.  Eur Neurol. 2000;  43 95-101
    CrossrefPubMedGoogle Scholar
  • 18 van Hilten J J, Wagemans E A, Ghafoerkhan S F et al. Movement characteristics in Parkinson’s disease: determination of dopaminergic responsiveness and threshold.  Clin Neuropharmacol. 1997;  20 402-408
    CrossrefPubMedGoogle Scholar
  • 19 Martinez-Martin P, Garcia Urra D, Balseiro Gomez J. Timed tests in Parkinson’s disease evaluation.  Mov Disord. 1997;  12 127-128
    CrossrefPubMedGoogle Scholar
  • 20 Defer G L, Widner H, Marie R M et al. Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD).  Mov Disord. 1999;  14 572-584
    CrossrefPubMedGoogle Scholar
  • 21 Goetz C G, Stebbins G T, Chumura T A et al. Teaching tape for the motor section of the unified Parkinson’s disease rating scale.  Mov Disord. 1995;  10 263-266
    CrossrefPubMedGoogle Scholar
  • 22 Hagell P. Timed tests in clinical assessment of motor function in Parkinson’s disease.  J Neurosci Nurs. 2000;  32 331-336
    CrossrefPubMedGoogle Scholar
  • 23 Jankovic J, Rajput A H, McDermott M P et al. The evolution of diagnosis in early Parkinsons disease. Parkinson Study Group.  Arch Neurol. 2000;  57 369-372
    CrossrefPubMedGoogle Scholar
  • 24 Linazasoro G. The apomorphine test in Parkinson’s disease: diagnostic value.  Neurologia. 1993;  8 288-290
    PubMedGoogle Scholar
  • 25 Roth J, Ruzicka E, Mecir P. The apomorphine test in the differential diagnosis of parkinsonism.  Cas Lek Cesk. 1994;  133 665-667
    PubMedGoogle Scholar
  • 26 Miranda M, Sacz D. Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease.  Rev Med Chil. 1995;  123 326-329
    PubMedGoogle Scholar
  • 27 Zappia M, Montesanti R, Colao R et al. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson’s disease.  Mov Disord. 1997;  12 103-106
    CrossrefPubMedGoogle Scholar
  • 28 Schwarz J, Tatsch K, Arnold G et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.  Neurology. 1993;  43 (S 06) 17-20
    PubMedGoogle Scholar
  • 29 D’Costa D F, Sheehan L J, Phillips P A et al. The levodopa test in Parkinson’s disease.  Age Ageing. 1995;  24 210-212
    CrossrefPubMedGoogle Scholar
  • 30 Fearnley J M, Lees A J. Ageing and Parkinson’s disease: substantia nigra regional selectivity.  Brain. 1991;  114 2283-2301
    CrossrefPubMedGoogle Scholar
  • 31 Gibb W R, Lees A J. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease.  Neuropathol Appl Neurobiol. 1989;  15 27-44
    CrossrefPubMedGoogle Scholar

PD Dr. med. Karla Eggert

Neurologische Klinik, Philipps-Universität Marburg

Rudolf-Bultmann-Str. 8

35039 Marburg

Email: eggert@med.uni-marburg.de

      >